Portland, OR -- (SBWIRE) -- 08/24/2017 -- BCG vaccine stands for the Bacillus Calmette Guerin vaccine intended for children and adults having high prevalence of tuberculosis (TB). The vaccine prevents from various forms of tuberculosis such as TB meningitis and military.

Access Full Summary@ https://www.alliedmarketresearch.com/BCG-vaccine-sales-market

The high prevalence of tuberculosis majorly drives the market growth. Furthermore, the increase in disease awareness and rise in government and private organizations investments fuel the BCG vaccine sales market. In addition, unmet demands in low and middle-income countries is anticipated to create new opportunities during the forecast period. However, lack of proper healthcare infrastructure is expected to restrain the growth of the market during the forecast period.

The market is segmented on the basis of drug type, indications, end user, and geography. Based on drug type, it is bifurcated into immune BCG and therapy BCG. Based on end-user, it is divided as pediatrics and adults. Based on indications the market is divided into tuberculosis and bladder cancer. Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Get Sample PDF@ https://www.alliedmarketresearch.com/request-toc-and-sample/2604

Bcg Vaccine Sales Market Key Segments:

By Drug Type

- Immune BCG
- Therapy BCG

By Indications

- Tuberculosis
- Bladder Cancer

By End User

- Pediatrics
- Adults

Key Players Profiled in the Report

- Merck & Co. Inc.
- Sanofi Pasteur
- Japan BCG Lab
- China National Biotec
- InterVax Ltd
- Serum Institute of India
- GreenSignal Bio Pharma Limited (GSBPL)
- Statens Serum Institute
- Shanyao Group
- Shanghai Institute of Biological Products